Exodus Point Capital Management, LP Agenus Inc Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$0.53 - $0.93 $505,313 - $886,681	-953,421 Reduced 96.62%	33,392 $19,000
Q3 2023 Nov 09, 2023	SELL	$1.12 - $1.88 $815,323 - $1.37 Million	-727,967 Reduced 42.45%	986,813 $1.12 Million
Q2 2023 Aug 10, 2023	BUY	$1.31 - $2.04 $2.25 Million - $3.5 Million	1,714,780 New	1,714,780 $2.74 Million
Q3 2022 Nov 10, 2022	BUY	$1.96 - $3.14 $113,150 - $181,272	57,730 Added 492.49%	69,452 $142,000
Q2 2022 Aug 19, 2022	SELL	$1.3 - $2.64 $652,668 - $1.33 Million	-502,053 Reduced 97.72%	11,722 $23,000
Q1 2022 May 13, 2022	BUY	$2.35 - $3.47 $46,513 - $68,681	19,793 Added 4.01%	513,775 $1.26 Million
Q4 2021 Feb 11, 2022	BUY	$2.92 - $5.74 $1.35 Million - $2.66 Million	463,844 Added 1539.07%	493,982 $1.59 Million
Q3 2021 Nov 15, 2021	BUY	$4.98 - $6.63 $33,062 - $44,016	6,639 Added 28.25%	30,138 $158,000
Q2 2021 Aug 16, 2021	BUY	$2.56 - $5.49 $60,157 - $129,009	23,499 New	23,499 $129,000
Q3 2020 Nov 16, 2020	SELL	$2.98 - $5.2 $118,151 - $206,169	-39,648 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.29 - $4.24 $90,793 - $168,107	39,648 New	39,648 $156,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.